Leqvio vs Losartan for Women: A Head-to-Head Comparison Across Special Populations

Why Women Are Asking About These Two Drugs Together

These two drugs do not compete in the same pharmacological lane. Inclisiran lowers LDL-cholesterol by silencing the gene that produces PCSK9, a protein that degrades LDL receptors. Losartan blocks angiotensin II type 1 receptors to lower blood pressure and reduce proteinuria. A woman is unlikely to be choosing between them in the way she might choose between two antihypertensives or two statins.

So why do women search for this comparison? Because cardiometabolic risk rarely arrives as one isolated number. A 48-year-old woman entering perimenopause may find her LDL climbing past 160 mg/dL and her blood pressure creeping above 130/80 mmHg at the same time, her clinician offers her two new prescriptions, and she wants to understand whether she actually needs both, one, or neither before she fills them.

This article does not declare a winner. It maps where each drug fits across the specific female life stages and conditions where the clinical picture gets complicated.

How Each Drug Works: The Mechanism Matters for Women

Inclisiran (Leqvio): Gene Silencing at the Liver

Inclisiran is a small interfering RNA (siRNA) delivered as a subcutaneous injection. It targets hepatic PCSK9 messenger RNA, reducing production of the PCSK9 protein. With less PCSK9, LDL receptors on liver cells are recycled rather than destroyed, so more LDL is cleared from circulation.

The dosing schedule sets it apart from every other lipid-lowering agent: one injection on day 1, a second at three months, then one injection every six months thereafter. In the ORION-10 and ORION-11 trials published in the New England Journal of Medicine in 2020, inclisiran reduced LDL-cholesterol by approximately 50% from baseline at day 510, sustained across the dosing interval. Those trials enrolled adults with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia who were already on maximally tolerated statin therapy.

Losartan: Daily Blood Pressure Control

Losartan is taken by mouth once daily, typically 25 to 100 mg depending on indication. It blocks the action of angiotensin II at the AT1 receptor, reducing vasoconstriction and aldosterone secretion. The result is lower blood pressure and, in the kidney, reduced intraglomerular pressure and proteinuria.

The landmark LIFE trial (Lancet, 2002) compared losartan to atenolol in 9,193 patients with hypertension and left ventricular hypertrophy. Losartan produced a 13% relative risk reduction in the primary composite of cardiovascular death, stroke, and myocardial infarction over a mean 4.8 years, driven largely by a 25% reduction in fatal and non-fatal stroke. The LIFE trial enrolled a meaningful proportion of women (approximately 54%), one of the more balanced sex distributions in a cardiovascular outcomes trial of that era.

LDL Cholesterol in Women: Why Inclisiran's Target Is Female-Relevant

The Estrogen Effect on Lipids

Estrogen raises HDL and lowers LDL. This is one reason premenopausal women, on average, carry a lower cardiovascular risk than age-matched men. The protection does not last. After menopause, LDL rises by an average of 10 to 14 mg/dL, and this shift happens over a relatively compressed window during the perimenopause transition. The Menopause Society (formerly NAMS) has noted that the perimenopausal period is associated with an atherogenic lipid shift independent of age alone.

A woman who managed her LDL adequately on a moderate-intensity statin at age 44 may find it no longer sufficient by age 50. This is the scenario where inclisiran becomes most relevant: as an add-on to maximally tolerated statin therapy when LDL remains above goal despite optimized oral treatment.

Familial Hypercholesterolemia: The Underdiagnosed Female Condition

Familial hypercholesterolemia (FH) affects approximately 1 in 250 people, yet women with FH are diagnosed less often and treated less aggressively than men. Women with FH carry a substantially elevated risk of premature ASCVD. Inclisiran is approved for heterozygous FH, making it a meaningful option for women whose LDL remains above 70 mg/dL on maximum statin plus ezetimibe. Losartan has no LDL-lowering effect and is not indicated for FH.

Blood Pressure in Women: Where Losartan Has No Rival

Hypertension Is Not Symmetrically Distributed by Sex

Hypertension prevalence is slightly lower in women than in men before age 55, then crosses and exceeds male prevalence after menopause. By age 65, more women than men have hypertension. The American Heart Association's 2023 hypertension statistics report that approximately 57% of women over 65 in the United States have hypertension, compared with 54% of men in that age group.

Losartan addresses this directly. Inclisiran does not lower blood pressure. If hypertension is the primary problem, inclisiran is not the answer.

CKD and Proteinuria: Losartan's Specific Niche

Women with diabetic nephropathy, lupus nephritis, or other causes of proteinuric CKD have a specific indication for an ARB. Losartan at 50 to 100 mg daily reduces proteinuria and slows the progression of CKD independent of its blood pressure effect. This renal protection is a feature of the class and is not shared with inclisiran.

Special Populations: Where the Comparison Gets Clinically Specific

PCOS

Polycystic ovary syndrome (PCOS) creates a cluster of cardiometabolic risks that can make both drugs relevant at different points in a woman's life. Women with PCOS carry higher rates of insulin resistance, dyslipidemia, and hypertension compared to BMI-matched controls. A 2023 systematic review in Fertility and Sterility found that LDL and triglycerides are both significantly elevated in women with PCOS, with a pattern that persists into perimenopause.

For a woman in her reproductive years with PCOS, losartan may be preferred over an ACE inhibitor for hypertension because it avoids the dry cough side effect that affects women at roughly twice the rate of men. However, both losartan and inclisiran are contraindicated in pregnancy, a critical consideration for a woman with PCOS who is not using reliable contraception.

Inclisiran's role in PCOS is less defined. Women with PCOS and FH represent a particularly high-risk subgroup where an LDL-lowering strategy beyond statins may be warranted, but no dedicated PCOS subgroup analyses exist from the ORION program. This is a data gap that should be acknowledged.

Perimenopause and Postmenopause

This is where the two drugs are most likely to be prescribed together, not instead of each other. A postmenopausal woman with:

• LDL 110 mg/dL on maximally tolerated rosuvastatin 20 mg
• Newly diagnosed stage 2 hypertension (145/92 mmHg)
• No contraindications to either agent

...could plausibly be a candidate for both inclisiran (for LDL) and losartan (for blood pressure). The drugs do not interact pharmacokinetically. Inclisiran is not metabolized by CYP enzymes and has no known drug-drug interactions with ARBs.

Type 2 Diabetes

Women with type 2 diabetes carry a disproportionately higher cardiovascular risk compared to diabetic men relative to their non-diabetic peers. The excess relative risk of coronary heart disease in diabetic women compared to non-diabetic women is approximately 44% higher than the analogous excess in diabetic men. This sex-specific risk gap means aggressive LDL lowering in diabetic women is clinically justified.

Losartan is a preferred antihypertensive in diabetic women with microalbuminuria or CKD. The two drugs target different pathways and may be used concurrently.

Chronic Kidney Disease

In women with CKD stages 3 to 4, both drugs require attention to renal parameters. Losartan can raise serum creatinine modestly (expected with reduced intraglomerular pressure) and may raise potassium, especially in women on potassium-sparing diuretics or with GFR below 30 mL/min. Monitoring potassium every 4 to 6 weeks after initiation is standard practice.

Inclisiran's pharmacokinetics in CKD: the drug is cleared by renal excretion, and the FDA prescribing information for inclisiran notes that patients with severe renal impairment (eGFR <30 mL/min) have not been studied in sufficient numbers to confirm safety equivalence. No dose adjustment is currently recommended by the manufacturer, but this is a data gap. Women with severe CKD should have an explicit conversation with their nephrologist before starting inclisiran.

Pregnancy, Lactation, and Contraception: Non-Negotiable Safety Information

Both drugs are contraindicated in pregnancy. This section is not optional reading.

Inclisiran in Pregnancy and Lactation

Inclisiran has no adequate human data in pregnancy. Animal studies showed fetal harm at doses exceeding clinical exposure levels. The FDA label classifies it as contraindicated in pregnancy. The FDA prescribing information states that inclisiran should be discontinued when pregnancy is detected, and that women of reproductive potential should use effective contraception during treatment and for a period thereafter.

The drug's twice-yearly injection schedule creates a specific consideration: inclisiran persists in hepatic tissue. The half-life of the active RISC-loaded strand in liver is estimated at 6 to 9 months. A woman who receives an injection in December and becomes pregnant in February may have significant drug exposure during organogenesis. Women of reproductive potential must use reliable contraception throughout treatment.

Lactation data for inclisiran is absent. Because siRNA molecules are large and expected to have low oral bioavailability in an infant, the theoretical risk is low, but "theoretical" is not the same as "studied." Breastfeeding while on inclisiran is not recommended until adequate data exist.

Losartan in Pregnancy and Lactation

Losartan carries a black box warning for fetal toxicity. The FDA label states that drugs acting on the renin-angiotensin system can cause fetal renal dysfunction, oligohydramnios, skeletal malformations, and neonatal death when used from the second trimester onward. First-trimester exposure carries lower but still real risk. ACOG recommends discontinuing ARBs as soon as pregnancy is confirmed and transitioning to pregnancy-safe antihypertensives such as labetalol, nifedipine, or methyldopa.

Losartan passes into human breast milk in small quantities in animal studies. Human lactation data are limited. The manufacturer advises against breastfeeding during treatment.

For women with PCOS or hypertension who are trying to conceive, losartan should ideally be discontinued before conception attempts begin, with a transition plan in place. This conversation should happen proactively with your clinician, not after a positive pregnancy test.

A Life-Stage Framework for Choosing Between These Drugs

No randomized head-to-head trial has compared inclisiran to losartan, and none is planned. The drugs serve different purposes. The following framework is original clinical synthesis developed for WomanRx based on the published literature and current guidelines.

| Life Stage | Dominant Cardiometabolic Risk | More Likely Relevant Drug | |---|---|---| | Reproductive years, PCOS, no TTC | Hypertension, insulin resistance | Losartan (if HTN + proteinuria) | | Trying to conceive | Stop both; switch to safe alternatives | Neither | | Pregnancy | Both contraindicated | Neither | | Postpartum / lactation | Avoid both; defer statin restart | Neither | | Perimenopause (LDL rising) | LDL elevation despite statin | Inclisiran | | Perimenopause (BP rising) | Stage 2 HTN, CKD, diabetes | Losartan | | Postmenopause, ASCVD history | Residual elevated LDL on max statin | Inclisiran (add-on) | | Postmenopause, CKD + proteinuria | Proteinuric kidney disease | Losartan | | Any stage with FH | Very high LDL refractory to statins | Inclisiran |

Most postmenopausal women with established cardiovascular disease and both elevated LDL and hypertension will be candidates for both agents simultaneously.

Side Effects: What Women Actually Experience

Inclisiran Side Effects

The most common adverse effect in ORION trials was injection-site reactions, occurring in approximately 8.2% of inclisiran recipients versus 1.8% of placebo recipients. These were generally mild (erythema, pain, bruising) and did not lead to discontinuation in the trials. No serious hepatic toxicity or muscle toxicity was observed at rates higher than placebo.

Women should be aware that flu-like symptoms were reported in a small percentage of participants in the weeks following injection. The twice-yearly schedule means that any injection-site reaction is a predictable, time-limited event rather than a daily nuisance.

Losartan Side Effects

Losartan is generally well tolerated. Unlike ACE inhibitors, it does not cause the persistent dry cough mediated by bradykinin accumulation. This matters for women: ACE inhibitor-associated cough is approximately twice as common in women as in men, making ARBs a preferred class when a woman cannot tolerate an ACE inhibitor.

The main safety concerns are hyperkalemia (especially with concurrent potassium-sparing agents or significant CKD) and hypotension with the first dose. Women who are volume-depleted from diuretics or who have autonomic instability should begin at 25 mg daily.

Dizziness is the most commonly reported symptom in clinical practice, particularly in older postmenopausal women.

Should You Switch From Leqvio to Losartan?

This question comes up in searches, but the premise is almost always based on a misunderstanding of what each drug does. Switching from inclisiran to losartan would make clinical sense only in a narrow scenario: a woman who was prescribed inclisiran off-label for a condition it does not treat, or where a clinician discovers the patient's primary unaddressed problem is actually hypertension rather than LDL elevation. That is a clinical correction, not a pharmacological substitution.

A switch away from inclisiran specifically raises the question of LDL rebound. Inclisiran's LDL-lowering effect wanes between injections but remains clinically meaningful throughout the dosing interval. Stopping inclisiran entirely without a replacement lipid-lowering strategy will allow LDL to return toward baseline over 6 to 12 months. For a woman with established ASCVD or FH, this is not a trivial risk.

If your clinician is recommending a change from inclisiran to another agent, the more likely alternative would be a PCSK9 monoclonal antibody (evolocumab or alirocumab), a higher-intensity statin, or the addition of ezetimibe. Losartan would not replace inclisiran's mechanism.

Monitoring and Practical Management

Inclisiran Monitoring

No routine lipid monitoring is required between injections as a safety check, but guidelines from the ACC/AHA recommend confirming LDL response 4 to 12 weeks after initiation to assess whether the treatment goal has been met. Liver function testing is not routinely required beyond standard care.

Women on inclisiran who are approaching a planned pregnancy should discuss stopping inclisiran at least one full dosing cycle (6 months) before attempting conception, given the drug's hepatic persistence, though formal guidance on this washout period does not yet exist in labeling.

Losartan Monitoring

Check serum potassium and creatinine at 2 to 4 weeks after initiation and after any dose increase. The American College of Cardiology recommends a potassium check within 1 to 2 weeks of starting an ARB in patients with CKD or diabetes. Blood pressure response should be assessed at 4 weeks. Ongoing monitoring every 6 to 12 months once stable.

Evidence Gaps for Women: What We Do Not Know

Women were included in both the ORION and LIFE trials, but sex-stratified analyses were not the primary prespecified endpoints in either program. In ORION-10 and ORION-11, approximately 29% of participants were women, which is a meaningful underrepresentation given that cardiovascular disease is the leading cause of death in women. Whether inclisiran's LDL-lowering magnitude or safety profile differs in postmenopausal women relative to the overall trial population is not reported in the primary publications.

For losartan, the LIFE trial's 54% female enrollment is better than most, but subgroup analyses specifically examining perimenopausal status, hormone therapy use, or PCOS were not conducted. The interaction between exogenous estrogen and ARB efficacy has not been formally studied.

Women with PCOS, autoimmune conditions, lupus nephritis, or a history of preeclampsia represent populations where both drugs may be clinically relevant but where trial data are thin. Clinicians extrapolate from general population trials. This is disclosed here so that you can ask your clinician what evidence specifically supports their recommendation for your profile.

Who This Is Right For (and Not Right For)

Inclisiran may be appropriate if you:

• Have established ASCVD or FH with LDL above goal despite maximally tolerated statin
• Are postmenopausal with LDL that has risen significantly since your estrogen decline
• Cannot tolerate daily oral lipid-lowering additions and prefer a twice-yearly injection
• Are not pregnant, not breastfeeding, and using reliable contraception

Inclisiran is not appropriate if you:

• Are pregnant, planning pregnancy within 6 to 12 months, or breastfeeding
• Have primary hypertension without a lipid problem
• Have severe renal impairment (eGFR <30 mL/min) without specialist guidance

Losartan may be appropriate if you:

• Have stage 1 or 2 hypertension, particularly with CKD or diabetes
• Had ACE inhibitor cough that stopped your previous antihypertensive
• Have proteinuric CKD at any age, including lupus nephritis
• Are postmenopausal with rising blood pressure and no current lipid gap

Losartan is not appropriate if you:

• Are pregnant or trying to conceive (switch to a safe alternative first)
• Have hyperkalemia or are taking potassium-sparing diuretics without careful monitoring
• Have primary hypercholesterolemia without a blood pressure indication